EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, and Biological Evaluation of 99m Tc‐Labeled Thalidomide Analogs as Novel Tumor‐Targeting Radiopharmaceuticals

Hassan M Rashed iD, Ashraf Mohamed Hamed Mohamed, Ibrahim H Eissa, Abdallah E Abdallah iD, Mohamed Ayman El-Zahabi iD, Tamer M Sakr iD

Journal of Labelled Compounds and Radiopharmaceuticals · 2026

DOI: 10.1002/jlcr.70045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Labelled Compounds and Radiopharmaceuticals, 2026. Verfasst von Hassan M Rashed und 5 weiteren Autor:innen. Beteiligte Einrichtung: Labeled Compounds Department, Hot Laboratories and Waste Management Center, Egyptian Atomic Energy Authority, Cairo, Egypt. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Thalidomide, Technetium, Drug Design. Die Arbeit nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to develop tumor‐selective radiopharmaceuticals for noninvasive imaging using three thalidomide analogs: N‐(2,6‐dioxopiperidin‐3‐yl)‐2‐((3‐ethyl‐7‐nitro‐4‐oxo‐3,4‐dihydroquinazolin‐2‐yl)thio)acetamide (DPDQA), 2‐amino‐N‐(2,6‐dioxopiperidin‐3‐yl)benzamide (ADPB), and 2‐(2‐chloroquinazolin‐4‐yl)hydrazine‐1‐carboxamide (CQHC). These compounds were radiolabeled with 99m Tc via a direct labeling method using sodium dithionite (Na 2 S 2 O 4 ) as a reducing agent. Optimal labeling conditions were determined by evaluating pH, ligand/reducing agent amounts, reaction time, and temperature. Radiochemical purity reached 92% ± 0.31% for 99m Tc‐DPDQA (pH 8, 500‐μg ligand, 500‐mg Na 2 S 2 O 4 , 15 min), 89.8% ± 0.128% for 99m Tc‐ADPB (pH 7, 800‐μg ligand, 25‐mg Na 2 S 2 O 4 , 15 min), and 92% ± 0.16% for 99m Tc‐CQHC (pH 10, 200‐μg ligand, 150‐mg Na 2 S 2 O 4 , 30 min). All complexes demonstrated good in vitro stability up to 24 h. In vivo biodistribution studies in tumor‐bearing mice revealed high tumor uptake ( T / NT ratios: 19.75, 6.18, and 22.72 for 99m Tc‐DPDQA, 99m Tc‐ADPB, and 99m Tc‐CQHC, respectively), with renal excretion as the primary clearance pathway. These results highlight the potential of 99m Tc‐labeled thalidomide analogs as selective tumor‐imaging agents outperforming existing agents like 99m Tc‐TEPA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiopharmaceuticalsThalidomideTechnetiumDrug DesignOrganotechnetium CompoundsAnimalsMiceIsotope LabelingTissue DistributionChemistry Techniques, Synthetic

Stichwörter der Autor:innen

SPECTTechnetium‐99 mradiolabelingradiopharmaceuticalsthalidomide analogstumor imaging

Substanzen

RadiopharmaceuticalsThalidomideTechnetiumOrganotechnetium Compounds

Autor:innen und Institutionen

  • Labeled Compounds Department, Hot Laboratories and Waste Management Center, Egyptian Atomic Energy Authority, Cairo, Egypt.
  • Radiation Protection Department, Nuclear and Radiological Regulatory Authority, Egyptian Atomic Energy Authority, Cairo, Egypt.
  • Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
  • Radioactive Isotopes and Generator Department, Hot Laboratories and Waste Management Center, Egyptian Atomic Energy Authority, Cairo, Egypt.

ORCID-Profile: Hassan M Rashed, Abdallah E Abdallah, Mohamed Ayman El-Zahabi, Tamer M Sakr

Zitieren

APA

Rashed, H. M., Mohamed, A. M. H., Eissa, I. H., Abdallah, A. E., El-Zahabi, M. A., & Sakr, T. M. (2026). Design, Synthesis, and Biological Evaluation of 99m Tc‐Labeled Thalidomide Analogs as Novel Tumor‐Targeting Radiopharmaceuticals. Journal of Labelled Compounds and Radiopharmaceuticals. https://doi.org/10.1002/jlcr.70045

Vancouver

Rashed HM, Mohamed AMH, Eissa IH, Abdallah AE, El-Zahabi MA, Sakr TM. Design, Synthesis, and Biological Evaluation of 99m Tc‐Labeled Thalidomide Analogs as Novel Tumor‐Targeting Radiopharmaceuticals. Journal of Labelled Compounds and Radiopharmaceuticals. 2026. doi:10.1002/jlcr.70045

BibTeX
@article{Rashed2026,
  author = {Rashed, Hassan M and Mohamed, Ashraf Mohamed Hamed and Eissa, Ibrahim H and Abdallah, Abdallah E and El-Zahabi, Mohamed Ayman and Sakr, Tamer M},
  title = {Design, Synthesis, and Biological Evaluation of 99m Tc‐Labeled Thalidomide Analogs as Novel Tumor‐Targeting Radiopharmaceuticals},
  journal = {Journal of Labelled Compounds and Radiopharmaceuticals},
  year = {2026},
  doi = {10.1002/jlcr.70045}
}
Kostenlos starten →